

【Therapeutic category】 625 Anti-virus agents
【Non-proprietary name】 Dolutegravir sodium/rilpivirine hydrochloride
【Safety measure】 PRECAUTIONS should be revised.

A revised description is underlined.

Current			Revision		
2. CONTRAINDICATIONS (This drug is contraindicated to the following patients.) Patients receiving rifampicin, carbamazepine, phenytoin, fosphenytoin sodium hydrate, phenobarbital, food containing St. John's Wort, apalutamide, enzalutamide, dexamethasone (systemic administration) (excluding single administration), and proton pump inhibitors (omeprazole, lansoprazole, rabeprazole sodium, esomeprazole magnesium hydrate, vonoprazan fumarate)			2. CONTRAINDICATIONS (This drug is contraindicated to the following patients.) Patients receiving rifampicin, carbamazepine, phenytoin, fosphenytoin sodium hydrate, phenobarbital, food containing St. John's Wort, apalutamide, enzalutamide, <u>ivosidenib, encorafenib, mitotane,</u> dexamethasone (systemic administration) (excluding single administration), and proton pump inhibitors (omeprazole, lansoprazole, rabeprazole sodium, esomeprazole magnesium hydrate, vonoprazan fumarate)		
10. INTERACTIONS 10.1 Contraindications for Co-administration (Do not co-administer with the following)			10. INTERACTIONS 10.1 Contraindications for Co-administration (Do not co-administer with the following)		
Drugs	Signs, symptoms, and treatment	Mechanism/risk factors	Drugs	Signs, symptoms, and treatment	Mechanism/risk factors

This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Apalutamide Enzalutamide	The blood concentrations of rilpivirine may decrease, leading to a reduction in the effect of this drug.	The CYP3A-inducing activity of these drugs promotes the metabolism of rilpivirine.	Apalutamide Enzalutamide <u>Ivosidenib</u> <u>Encorafenib</u> <u>Mitotane</u>	The blood concentrations of rilpivirine may decrease, leading to a reduction in the effect of this drug.	The CYP3A-inducing activity of these drugs promotes the metabolism of rilpivirine.
-----------------------------	--	--	---	--	--

This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.